Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Active, not recruiting · Phase 3 · NCT06332534
Conditions: Crohn's Disease
At a glance
- Research payments reported, 2025
- $478,556
- U.S. investigators named
- 15
- Sites paid
- 21
- Planned or actual enrollment
- 111
About the trial
- Sponsor
- AbbVie
- Tested
- Upadacitinib (drug)
- Dates
- Started 2024-08-08; completion 2031-01
- Results posted
- Not yet
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective oral Upadacitinib is in treating moderately to severely active Crohn's Disease in pediatric participants aged 2 to 18 years old who have had inadequate response, loss of response, intolerance, or medical contraindications to corticosteroids, immunosuppressants, and/or biologic therapy. Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active CD and is being develo…
From ClinicalTrials.gov, last updated 2026-10-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $478,556 in research payments for this study in 2025 (93 payments).
Products named: Rinvoq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sabina A. Ali, MD Pediatric Gastroenterology · Oakland, CA
- Jonathan D. Moses, MD Pediatric Gastroenterology · Palo Alto, CA
- Edward Hoffenberg, MD Pediatric Gastroenterology · Aurora, CO
- Jeffrey S. Hyams, MD Pediatric Gastroenterology · Hartford, CT
- Xiaoyi Zhang, M.D., PH.D. Pediatric Gastroenterology · Indianapolis, IN
- Ian K. Kang, M.D. Pediatric Gastroenterology · Baton Rouge, LA
- Athos Bousvaros, MD, MPH Pediatric Gastroenterology · Boston, MA
- Ramalingam Arumugam, MD Pediatric Gastroenterology · Saint Paul, MN
- David S. Dunkin, M.D. Pediatric Gastroenterology · New York, NY
- Thomas J. Sferra, MD Pediatric Gastroenterology · Cleveland, OH
- Lindsey G. Albenberg, DO Pediatric Gastroenterology · Philadelphia, PA
- Antonio I. Del Valle, M.D. Pediatric Gastroenterology · San Juan, PR
- Leonardo R. Hormaza, M.D. Pediatric Gastroenterology · Santurce, PR
- Edwin J. Torres Reyes, MD Pediatric Gastroenterology · Arecibo, PR
- Matthew D. Egberg, M.D. Student in an Organized Health Care Education/Training Program · Madison, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Osf Little Company of Mary Medical Center, IL $81,097
- Uh Cleveland Medical Center, OH $77,766
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $76,451
- Indiana University $65,072
- Clinical Research Investigator $63,138
- Children's Hospital Colorado, CO $31,702
- Connecticut Childrens Medical Center, CT $25,770
- Univ of Nc Chapel Hill $21,689
- Mngi Digestive Health PA $20,228
- Icahn School of Med at Mt Sinai $7,086
- Children's Hospital of Philadelphia, PA $6,264
- Osf Heart of Mary Medical Center, IL $303
- Plymouth Endoscopy Center and Clinic $303
- Indiana University Health Center $303
- Clinical Research Investigator Group $303
- Puerto Rico Health and Wellness Institute LLC $303
- Mount Sinai School of Medicine $303
- University of North Carolina at Chapel Hill $245
- Stanford University School of Medicine $93
- Boston Children's Hospital, MA $68
- Clinical Research Puerto Rico $68
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.